Discover Info About This Treatment Option For Certain Patients With Renal Cell Carcinoma. FDA-Approved First-Line Treatment Option For Certain Patients With Renal Cell Carcinoma.
24.12-0.02 (-0.08%)
at Fri, May 24, 2024, 4:00PM EDT - U.S. markets closed
Delayed Quote